CClinicalTrials.gg
Sign In
CompletedNCT04540965Updated Mar 9, 2021

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

A Phase 1 interventional study of Telaglenastat and Famotidine in Drug Interaction, sponsored by Calithera Biosciences, Inc. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-09.

Sponsored by Calithera Biosciences, Inc · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 9 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is designed to formally evaluate the impact of famotidine, an H2R antagonist, on the pharmacokinetics of telaglenastat.

This study will be conducted in up to 22 healthy volunteers, who meet all of the inclusion criteria and none of the exclusion criteria. The study is double-blinded, randomized 2-way crossover in design.

Subjects will receive four 200 mg tablets of telaglenastat either in the presence or absence of 20 mg famotidine (H2R-antagonist) with a 4-day wash-out period in between each regimen.

02

Conditions studied

  • Drug Interaction
03

In context

Lead sponsor

Calithera Biosciences, Inc is the lead sponsor of 29 studies on the registry; none are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 10 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Healthy adult male or female, 18-55 years of age, inclusive, at screening.
  2. Has not used nicotine-containing products (more than 5 cigarettes/equivalent per week) for at least 3 months prior the first dose and has negative urine cotinine tests at screening, Day 1 and Day 7.
  3. Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusively, at screening.
  4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the Principal Investigator (PI).

  5. For a female of childbearing potential: either be sexually inactive (abstinent - ie, not sexually active with a male partner) for 14 days prior to the first dose and through 14 days following the last dose of any study drug(s) or be using one of the following acceptable birth control methods:

    1. Non-hormone releasing intrauterine device in place for at least 3 months prior to the first dose of any study drug with a physical barrier method (eg, condom, diaphragm) from the time of screening through the last dose of any study drug. A progesterone (progestin)-only contraceptive is allowable.
    2. A physical barrier method (eg, condom, diaphragm) for at least 14 days prior to the first dose of any study drug and until the last dose of any study drug.
  6. In addition, female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method until the last dose of any study drug.

  7. Females of non-childbearing potential as defined below do not require contraception.

    Females of non-childbearing potential:

    1. must have undergone one of the following sterilization procedures at least 6 months prior to the first dose of any study drug:

      1. hysteroscopic sterilization;
      2. bilateral salpingectomy;

    <!-- -->

    1. Women with a tubal ligation less than one year prior to study start must agree to use a barrier method of birth control 3. non-surgical transcervical sterilization (eg, Essure®); 4. hysterectomy; 5. bilateral oophorectomy OR
    2. be postmenopausal with amenorrhea for at least 1 year prior to the first telaglenastat dose with follicle-stimulating hormone (FSH) serum levels > 30 IU/mL.

  8. A non-vasectomized male subject must agree to use a physical barrier (eg, condom or diaphragm) or abstain from sexual intercourse with female partners during the study until the last dose of any study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to study start. A male who has been vasectomized less than 4 months prior to study start must follow the same restrictions as a non-vasectomized male).

    a) Female participants with a vasectomized male partner, or male participants with a female partner of non-childbearing potential do not require contraception.

  9. If male, must agree not to donate sperm from dosing until the last dose of any study drug.
  10. Alanine and aspartate aminotransferase and bilirubin levels ≤ the upper limit of normal or deemed not clinically significant by the Investigator.
  11. Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or is expected to manifest significant emotional problems during the conduct of the study.
  2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI.
  3. History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  4. History or presence of alcoholism or drug abuse within the past 2 years prior to screening.
  5. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or inactive ingredient(s).

  6. History or presence of:

    1. liver disease, pancreatic insufficiency or intestinal malabsorption;
    2. neuropathy or muscle disorders;
    3. seizures;
    4. asthma; childhood asthma that has resolved and has not required medical treatment for at least 5 years prior to study start is permitted;
    5. fluid retention;
    6. cardiovascular disease, cardiac arrhythmias, hypertension, cardiovascular thrombotic events, myocardial infarction, or stroke;
    7. ulcer disease or gastrointestinal bleeding;
    8. renal papillary necrosis and other renal injury;
    9. exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
  7. Female subjects who are pregnant or lactating.
  8. Positive urine drug or alcohol results at screening or check-in.
  9. Positive urine cotinine at screening or check-in.
  10. Positive results at screening for HIV types 1 and 2, HBsAg, or hepatitus C virus.
  11. Seated blood pressure (taken after 5 minutes in a sitting position) is less than 90/40 mmHg or greater than 140/90 mmHg at screening and not as part of ECG.
  12. Seated heart rate (taken after 5 minutes in a sitting position) is lower than 40 bpm or higher than 100 bpm at screening and not as part of ECG.
  13. QTcF interval is > 460 msec (males) or > 480 msec (females) or deemed clinically abnormal by the PI at screening.
  14. Estimated creatinine clearance \< 90 mL/min calculated by the method of Cockcroft and Gault at screening.

  15. Unable to refrain from or anticipates the use of:

    1. Proton pump inhibitors (PPIs), histamine H2 receptor antagonists (H2RAs), buffering agents (eg, Tums) or any other medication that may have an effect on gastric acid secretion beginning 14 days prior to the first dose of any study drug and throughout the study.
    2. Any non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dose of any study drug and throughout the study.
    3. Any prescription medications (including hormone replacement therapy and lithium) beginning 14 days prior to the first dose of any study drug and throughout the study.
  16. Donation of blood or significant blood loss within 56 days prior to the first dose of any study drug.
  17. Plasma donation within 14 days prior to the first dose of any study drug.
  18. Presence of any medical history or condition that may limit gastric drug absorption (eg, prior gastric surgery, gastric banding, Whipple procedure)
  19. Participation in another clinical trial within 28 days prior to the first dose of any study drug. The 28-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Telaglenastat and Famotidine

    Famotidine

    Drug: Telaglenastat · Drug: Famotidine

  • Placebo comparator
    Telaglenastat and Placebo for Famotidine

    Placebo for famotidine

    Drug: Telaglenastat · Drug: Placebo for famotidine

Interventions

  • DrugTelaglenastat

    Glutaminase inhibitor

    Also known as: CB-839

  • DrugFamotidine

    Histamine-H2 Receptor Antagonist

    Also known as: Pepcid

  • DrugPlacebo for famotidine

    Placebo for Histamine-H2 Receptor Antagonist

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    To assess the effect of famotidine on the Cmax of telaglenastat in healthy adult subjects

    Time frame: Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat

  2. Time to peak plasma concentration (Tmax)

    To assess the effect of famotidine on the Tmax of telaglenastat in healthy adult subjects

    Time frame: Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat

  3. Area under the concentration-time curve from time = 0 to the last determination (AUClast)

    To assess the effect of famotidine on the time to maximum plasma concentration (Tmax) of telaglenastat in healthy adult subjects.

    Time frame: Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat with and without famotidine.

  4. Area under the concentration-time curve from time = 0 to infinity (AUC0-inf)

    To assess the effect of famotidine on the AUC0-inf of telaglenastat in healthy adult subjects

    Time frame: Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat with and without famotidine.

  5. Half-life

    To assess the effect of famotidine on the half-life of telaglenastat in healthy adult subjects

    Time frame: Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat with and without famotidine.

  6. Elimination rate

    To assess the effect of famotidine on the elimination rate of telaglenastat in healthy adult subjects

    Time frame: Blood samples taken on Day 3 and Day 9 at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24 hours post administration of the telaglenastat with and without famotidine.

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Assessed by physician reports of any unfavorable and unintended sign, symptom, or disease (new or exacerbated) that is temporally associated with the use of the investigational products.

    Time frame: Safety will be assessed throughout the study, starting from Day 3, prior to receiving the first dose of telaglenastat through to Day 11 when the subjects are released from the clinical site.

  2. Incidence of changes in body temperature

    Body temperature is measured in degrees Celsius.

    Time frame: Body temperature will be assessed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  3. Incidence of changes in respiratory rate.

    Respiratory rate is measured in breaths per minute.

    Time frame: Respiratory rate will be assessed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  4. Incidence of changes in blood pressure

    Blood pressure is measured in mmHg.

    Time frame: Blood pressure will be assessed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  5. Incidence of changes in heart rate.

    Heart rate is measured in beats per minute.

    Time frame: Heart rate will be assessed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  6. Electrocardiograms (ECGs)

    Triplicate 12-lead ECGs including P Wave, QRS Complex, and QTcF determination

    Time frame: ECGs will be performed prior to and 4 hours after telaglenastat dosing on Days 3 and 10 and 24 hours after telaglenastat dosing on Days 4 and 11.

  7. Hemoglobin assessments

    Hemoglobin will be measured in g/dL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  8. Hematocrit assessments

    Hematocrit will be measured in %

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  9. Leukocyte count assessments

    Leukocyte count will be measured in 1000 cells/microliter

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  10. Red blood cell count assessments

    Red blood cell count will be measured in 1,000,000 cells/microliter

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  11. Platelet count assessments

    Platelet count.will be measured in 1000 cells/microliter

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  12. Serum urea

    Serum Urea will be measured in mg/dL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  13. Serum bilirubin

    Serum Bilirubin will be measured in micromoles/L

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  14. Serum alkaline phosphatase

    Serum alkaline phosphatase will be measured in units/L

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  15. Serum Aspartate aminotransferase assessments

    Serum Aspartate aminotransferase will be measured in units/L

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  16. Serum aspartate aminotransferase

    Serum Alanine aminotransferase will be measured in units/L

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  17. Serum albumin

    Serum Albumin will be measured in g/dL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  18. Serum sodium

    Serum Sodium will be measured in meq/L

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  19. Serum potassium

    Serum Potassium will be measured in meq/L

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  20. Serum chloride

    Serum Chloride will be measured in meq/L

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  21. Serum glucose

    Serum Glucose will be measured in mg/dL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  22. Serum creatinine

    Serum Creatinine will be measured in mg/dL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  23. Urine pH

    Urine pH will be measured in units

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  24. Urine Specific gravity

    Urine Specific gravity will be measured in g/mL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  25. Urine Protein

    Urine Protein will be measured in mg/24 hr

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  26. Urine Glucose

    Urine Glucose will be measured in mg/dL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  27. Urine Ketones

    Urine Ketones will be measured in mg/dL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  28. Urine Bilirubin

    Urine Bilirubin will be measured in mg/dL

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  29. Urine Blood

    Urine Blood will be measured in RBC/high powered field

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  30. Urine Nitrite

    Urine Nitrite will be measured by dipstick

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  31. Urine Urobilinogen

    Urine Urobilinogen will be measured in Ehrlich units

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

  32. Urine Leukocyte esterase.

    Urine Leukocyte esterase will be measured in units

    Time frame: Assessments will be performed prior to dosing with telaglenastat on Days 2 and 9 and 24 hours after dosing on Days 4 and 11.

07

Study locations

1 site
  • Nucleus Network Brisbane Clinic (formerly Q-Pharm)
    Brisbane, Queensland Herston QLD 4006, Australia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04540965
Lead sponsor
Calithera Biosciences, Inc
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Sep 22, 2020
Primary completion
Dec 8, 2020
Completion
Dec 8, 2020
Last update
Mar 9, 2021

Study contacts

Paul Griffin, Dr.
principal investigator · Nucleus Network

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Calithera Biosciences, Inc

Start the discussion